MARKET

IMRA

IMRA

Imara Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.92
-0.46
-6.23%
After Hours: 6.92 0 0.00% 16:00 04/16 EDT
OPEN
7.35
PREV CLOSE
7.38
HIGH
7.38
LOW
6.85
VOLUME
96.03K
TURNOVER
--
52 WEEK HIGH
62.71
52 WEEK LOW
6.85
MARKET CAP
121.62M
P/E (TTM)
-1.1022
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13)
Benzinga · 3d ago
Global Marine Chains Professional Size, Share, Value, and Competitive Landscape 2020
Apr 13, 2021 (Heraldkeepers) -- Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation. Product values and regional...
Heraldkeepers · 4d ago
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12)
Benzinga · 4d ago
The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7)
Benzinga · 04/08 12:14
The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 6)
Benzinga · 04/07 11:57
Marine Fin Stabilizer Professional Survey Global Market Growth, Status and Outlook Research Report 2021
Apr 02, 2021 (Heraldkeepers) -- Ship stabilizers (or stabilisers) are fins or rotors mounted beneath the waterline and emerging laterally from the hull to...
Heraldkeepers · 04/02 11:01
BRIEF-Imara Inc Enters Into Controlled Equity Offering Sales Agreement Pursuant To Which Co May Issue, Sell Shares Of Co's Common Stock Of Up To $75 Million
reuters.com · 04/01 22:43
BRIEF-Imara Inc Files For Mixed Shelf Of Up To $200 Million
reuters.com · 04/01 21:26
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMRA. Analyze the recent business situations of Imara Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMRA stock price target is 37.50 with a high estimate of 42.00 and a low estimate of 33.00.
EPS
Institutional Holdings
Institutions: 42
Institutional Holdings: 11.66M
% Owned: 66.36%
Shares Outstanding: 17.58M
TypeInstitutionsShares
Increased
23
457.32K
New
3
18.80K
Decreased
3
26.11K
Sold Out
2
18.79K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Independent Director
David Mott
President/Chief Executive Officer/Director
Rahul Ballal
Chief Financial Officer/Chief Operating Officer/Primary Contact
Michael Gray
Senior Vice President
Lynette Hopkinson
Director
Edward Conner
Independent Director
Mette Agger
Independent Director
David Bonita
Independent Director
Mark Chin
Independent Director
Barbara Dalton
Independent Director
Carl Goldfischer
Independent Director
Sara Nayeem
No Data
About IMRA
Imara, Inc. is a clinical-stage biopharmaceutical company. The Company is developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. The Company’s product pipeline include IMR-687, which is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease (SCD), and beta-thalassemia. Its IMR-687 is a selective, small molecule inhibitor of phosphodiesterase-9 (PDE9). The Company is conducting a Phase 2a clinical trial of IMR-687 in adult patients with SCD and a Phase 2b clinical trial for the treatment of patients with beta-thalassemia.

Webull offers kinds of Imara Inc stock information, including NASDAQ:IMRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMRA stock methods without spending real money on the virtual paper trading platform.